Shanghai Fosun Pharmaceutical (Group) Co., Ltd. - 27 Jun 2025 Form 4 Insider Report for NATURES SUNSHINE PRODUCTS INC (NATR)

Role
10%+ Owner
Signature
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. By: /s/ Yuqing Chen, Chairman
Issuer symbol
NATR
Transactions as of
27 Jun 2025
Net transactions value
-$32,713,796
Form type
4
Filing time
27 Jun 2025, 16:27:23 UTC
Previous filing
17 Oct 2024
SEC
View on sec.gov

Reporting Owners (2)

Name Relationship Address Signature Signature date CIK
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. 10%+ Owner BUILDING A,, NO. 1289 YISHAN ROAD, SHANGHAI, CHINA Shanghai Fosun Pharmaceutical (Group) Co., Ltd. By: /s/ Yuqing Chen, Chairman 27 Jun 2025 0001615258
Fosun Pharma USA Inc. 10%+ Owner 104 CARNEGIE CENTER DRIVE, SUITE 204, PRINCETON Fosun Pharma USA Inc. By: /s/ Yuqing Wang, Chief Financial Officer 27 Jun 2025 0002071437

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NATR Common Stock Sale $32,713,796 -2,854,607 -100% $11.46 0 27 Jun 2025 by Fosun Pharma USA Inc. F1, F2
holding NATR Common Stock 64,167 27 Jun 2025 by Fosun Industrial Co., Limited F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The shares were sold pursuant to that certain Underwriting Agreement. dated June 25, 2025, among Fosun Pharma USA Inc., the Issuer, and the underwriter party thereto.
F2 Fosun Pharma USA Inc. is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
F3 Fosun Industrial Co., Limited is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.